Clindamycin phosphate 1.2%- tretinoin 0.025% gel: vehicle characteristics, stability, and tolerability

Cutis. 2008 May;81(5):405-8.

Abstract

An aqueous gel formulation containing solubilized clindamycin phosphate 1.2% and a stable combination of both solubilized and crystalline tretinoin 0.025% (clin/tret) has been evaluated in 3 pivotal phase 3 studies, among other studies including a 52-week trial. The pivotal studies enrolled 4550 participants 12 years and older with mild, moderate, and severe acne vulgaris. The combination clin/tret gel was effective in reducing both inflammatory and noninflammatory lesions and was well-tolerated. This article reviews important vehicle characteristics of the combination gel as well as formulation stability and tolerability data that are potentially clinically relevant.

Publication types

  • Review

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Administration, Cutaneous
  • Anti-Bacterial Agents* / administration & dosage
  • Anti-Bacterial Agents* / adverse effects
  • Anti-Bacterial Agents* / chemistry
  • Anti-Bacterial Agents* / pharmacology
  • Benzoyl Peroxide / pharmacology
  • Clindamycin / administration & dosage
  • Clindamycin / adverse effects
  • Clindamycin / analogs & derivatives*
  • Clindamycin / chemistry
  • Clindamycin / pharmacology
  • Dermatitis, Irritant / etiology
  • Dermatologic Agents* / administration & dosage
  • Dermatologic Agents* / adverse effects
  • Dermatologic Agents* / chemistry
  • Dermatologic Agents* / pharmacology
  • Drug Combinations
  • Drug Interactions
  • Drug Stability
  • Gels
  • Humans
  • Pharmaceutical Vehicles / chemistry
  • Pharmaceutical Vehicles / pharmacology
  • Skin Absorption
  • Tretinoin* / administration & dosage
  • Tretinoin* / adverse effects
  • Tretinoin* / chemistry
  • Tretinoin* / pharmacology

Substances

  • Anti-Bacterial Agents
  • Dermatologic Agents
  • Drug Combinations
  • Gels
  • Pharmaceutical Vehicles
  • Clindamycin
  • Tretinoin
  • clindamycin phosphate
  • Benzoyl Peroxide